deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced - breast cancer (mBC) metastatic/advanced - breast cancer (mBC)

versus chemotherapy
trastuzumab deruxtecan vs. chemotherapy 1 certainty unassessablestatistically conclusive-33% certainty unassessablestatistically conclusive-46%-